# Bill Baumel

> Bill Baumel is a Series A investor at Ohio Innovation Fund backing Health Care and Software. See 26 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Ohio Innovation Fund](https://shizune.co/investors/profile/ohio-innovation-fund)
- Location: Columbus, United States
- Total investments: 26
- Last investment: Jan 2024
- Lead investor: 31%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/billbaumel/
- X (Twitter): https://twitter.com/OhioInnoFund
- Website: https://www.ohioinnovationfund.com/

Bill Baumel is a Series A investor at Ohio Innovation Fund in Columbus focused on Health Care and Software. Bill is a seasoned venture capitalist who spent 20+ years working in Silicon Valley before returning to his home state to start the Ohio Innovation Fund. His investment areas include SaaS, big data, cyber security and medtech, resulting in four IPOs and 10 major acquisitions by Dell, SAP, Medtronic, Intuit, and Stryker among others. At OIF, heworks in the trenches with Ohio-based entrepreneurs to rapidly scale their companies and drive the growth of Ohio's entrepreneurial ecosystem. His companies have secured the majority of the Fortune 500 as customers, and their strategic partners include Microsoft, Facebook, SAP, Sanofi, Citi and more. They swept both early and late-stage TechOhio Culture Awards in 2018, as well as earned the title of Best Early Stage Company in Ohio for three consecutive years. He earned a BSBA summa cum laude from The Ohio State University and an MBA with high distinction from the University of Michigan.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 8 | 31% |
| Software | 7 | 27% |
| Medical | 6 | 23% |
| Medical Device | 5 | 19% |
| Big Data | 2 | 8% |

51 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 8 | 31% |
| Series B | 6 | 23% |
| Series C | 5 | 19% |
| Funding Round | 4 | 15% |
| Seed | 2 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Clarametyx Biosciences | Clarametyx Biosciences is a late preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms. | $33M | Series A | Jan 05, 2024 |  |
| Genetesis | Genetesis is a rapidly growing medical technology company redefining the way patients with a risk of myocardial ischemia and coronary artery disease are clinically diagnosed, monitored and screened. | $17.5M | Series C | Oct 06, 2022 |  |
| Enable Injections | Enable Injections develops and manufactures wearable drug delivery systems centered on the enFuse platform, a body-worn technology that enables subcutaneous administration of large-volume pharmaceutical and biologic therapies without traditional intravenous methods. The company focuses on engineering devices that allow patients to receive treatmentthrough simple, hands-free injections under the skin while collaborating with pharmaceutical partners to integrate its delivery systems with specific therapies. Its services encompass design, clinical support, manufacturing, and supply of combination products built around the enFuse technology. Enable Injections engages in partnerships to expand application of its delivery systems across varied therapeutic areas and supports regulatory and commercialization planning with its collaborators. | $215M | Series C | Jan 27, 2022 |  |
| Aware | Aware is a cloud intelligence platform that adopts the latest advancements in cognitive computing, artificial intelligence, and behavioral analytics to amplify enterprise value by monitoring the social graph. They harness the power of their platform’s insights into human behavior and interactivity to create great value for the enterprise. | $60M | Series C | Oct 13, 2021 |  |
| S4 Medical | Sotera is a medical device company focused on innovative solutions for cardiac procedures. The company’s initial product is a solution for reducing complications to the esophagus during catheter ablation treatment for atrial fibrillation.It is commercializing a novel medical device designed to protect the esophagus during catheter ablationprocedures. | $3M | Series A | Apr 02, 2021 |  |
| eFuse | eFuse is a web and mobile application for the Esports & Video Game industry. eFuse allows individuals to establish their gaming identity and participate in the industry at all levels. Whether it be learning about the industry, networking with other like-minded individuals, or accessing opportunities like jobs & scholarships, eFuse hassomething for everyone. | $6M | Venture - Series Unknown | Feb 18, 2021 |  |
| Aware | Aware is a cloud intelligence platform that adopts the latest advancements in cognitive computing, artificial intelligence, and behavioral analytics to amplify enterprise value by monitoring the social graph. They harness the power of their platform’s insights into human behavior and interactivity to create great value for the enterprise. | $12M | Series B | Dec 14, 2020 |  |
| ScriptDrop | ScriptDrop’s technology platform enables connectivity across the healthcare ecosystem connecting patients, pharmacists, providers, and pharmaceutical manufacturers. The platform provides a seamless experience for patients, offering them prescription delivery in all 50 states and allowing for important additional services to be provided for betteradherence.The company was founded in 2016 and is headquartered in Columbus, Ohio. | $15M | Series A | Oct 01, 2020 |  |
| Immuta | Immuta provides a cloud-native data governance platform for organizations to automate data access control, security, and privacy compliance, ensuring each user who queries data sees only the data they’re supposed to see, for their approved purpose or role. The platform aims to create trust across data engineering, security, legal, compliance, andbusiness teams so they can work together to ensure timely access to critical data with minimal risk while adhering to global data privacy regulations including the GDPR, CCPA, and HIPAA. | $40M | Series C | Jun 23, 2020 |  |
| S4 Medical | Sotera is a medical device company focused on innovative solutions for cardiac procedures. The company’s initial product is a solution for reducing complications to the esophagus during catheter ablation treatment for atrial fibrillation.It is commercializing a novel medical device designed to protect the esophagus during catheter ablationprocedures. |  | Venture - Series Unknown | Feb 17, 2020 |  |

10 of 26 investments shown.

## Co-investors
- [JumpStart Inc.](https://shizune.co/investors/profile/jumpstartinc) — VC Fund, 8 deals together
- [JobsOhio](https://shizune.co/investors/profile/jobsohio) — VC Fund, 5 deals together
- [Rev1 Ventures](https://shizune.co/investors/profile/techcolumbus-2) — VC Fund, 5 deals together
- [North Coast Ventures](https://shizune.co/investors/profile/north-coast-angel-fund) — VC Fund, 4 deals together
- [Advantage Capital](https://shizune.co/investors/profile/advantage-capital-partners) — VC Fund, 3 deals together
- [CincyTech](https://shizune.co/investors/profile/cincytech) — VC Fund, 3 deals together

## About Ohio Innovation Fund

VC Fund · Columbus, United States

We partner with bold, visionary founders & disruptive companies to create industries of the future.

5 contacts available at Ohio Innovation Fund.

| Name | Title | Profile |
| --- | --- | --- |
| Bill Baumel | Managing Director | https://shizune.co/investors/profile/bill-baumel |
| Faith Voinovich | Principal | https://shizune.co/investors/profile/faith-voinovich |
| Michael Hughes | Venture Partner | https://shizune.co/investors/profile/michael-hughes-3 |
| Michael Triplett | Venture Advisor | https://shizune.co/investors/profile/michael-triplett |
| Michael Triplett | Venture Advisor | https://shizune.co/investors/profile/t-michael-triplett |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Bill Baumel invest in?

Bill Baumel invests primarily in Health Care, Software and Medical startups, most often at Series A and Series B stage. Most of the 26 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Bill Baumel last invest?

The most recent investment recorded for Bill Baumel closed in Jan 2024. Shizune tracks 26 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co